microRNA information: hsa-miR-125a-3p
Section | ID | link |
---|---|---|
Mature name: | hsa-miR-125a-3p | miRbase |
Accession: | MIMAT0004602 | miRbase |
Precursor name: | hsa-mir-125a | miRbase |
Precursor accession: | MI0000469 | miRbase |
Symbol: | MIR125A | HGNC |
RefSeq ID: | NR_029693 | GenBank |
Sequence: | ACAGGUGAGGUUCUUGGGAGCC |
Reported expression in cancers: hsa-miR-125a-3p
miRNA | cancer | regulation | reporting | PUBMED | method |
---|---|---|---|---|---|
hsa-miR-125a-3p | cervical and endocervical cancer | downregulation | "MiR-125a has been characterized as a tumor suppres ......" | 26389681 | |
hsa-miR-125a-3p | colorectal cancer | upregulation | "Clinicopathological significance of microRNA 21 an ......" | 19921579 | qPCR |
hsa-miR-125a-3p | colorectal cancer | deregulation | "One of the most up-regulated miRNAs miRNA-106a was ......" | 21671476 | qPCR |
hsa-miR-125a-3p | colorectal cancer | downregulation | "Hypermethylation Associated Silencing of miR 125a ......" | 26693202 | Reverse transcription PCR; qPCR |
hsa-miR-125a-3p | gastric cancer | downregulation | "Down regulation of miR 125a 3p in human gastric ca ......" | 22322911 | qPCR |
hsa-miR-125a-3p | liver cancer | upregulation | "Studies have been shown that miR-125a plays an imp ......" | 22768249 | qPCR |
hsa-miR-125a-3p | lymphoma | downregulation | "Clinical and epidemiological data suggest that chr ......" | 22307176 | Reverse transcription PCR; in situ hybridization |
hsa-miR-125a-3p | ovarian cancer | downregulation | "miRNA mimics and miRNA inhibitors were used in qua ......" | 26646586 | qPCR |
hsa-miR-125a-3p | ovarian cancer | downregulation | "The miR-125a was downregulated in several types of ......" | 27133078 | |
hsa-miR-125a-3p | prostate cancer | deregulation | "Upregulation of miR-122 miR-335 miR-184 miR-193 mi ......" | 23781281 | |
hsa-miR-125a-3p | sarcoma | upregulation | "There were 21 significantly up-regulated miRNAs in ......" | 21213367 | |
hsa-miR-125a-3p | sarcoma | upregulation | "In addition we found that curcumin suppressed the ......" | 27231954 |
Reported cancer pathway affected by hsa-miR-125a-3p
miRNA | cancer | pathway | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-125a-3p | acute myeloid leukemia | cell cycle pathway; Apoptosis pathway | "miR 125a regulates cell cycle proliferation and ap ......" | 24484870 | |
hsa-miR-125a-3p | breast cancer | Apoptosis pathway | "MicroRNA 125a represses cell growth by targeting H ......" | 19875930 | |
hsa-miR-125a-3p | breast cancer | Apoptosis pathway | "Functional cooperation of miR 125a miR 125b and mi ......" | 23519125 | |
hsa-miR-125a-3p | breast cancer | Apoptosis pathway | "HDAC inhibitors target HDAC5 upregulate microRNA 1 ......" | 25531695 | |
hsa-miR-125a-3p | breast cancer | Hippo signaling pathway | "MicroRNA 125a influences breast cancer stem cells ......" | 25962054 | |
hsa-miR-125a-3p | cervical and endocervical cancer | Epithelial mesenchymal transition pathway; cell cycle pathway | "MiR 125a suppresses tumor growth invasion and meta ......" | 26389681 | Luciferase |
hsa-miR-125a-3p | cervical and endocervical cancer | Apoptosis pathway | "MiR 125a promotes paclitaxel sensitivity in cervic ......" | 26878391 | |
hsa-miR-125a-3p | colon cancer | Apoptosis pathway | "miR 125a 5p inhibits cell proliferation and induce ......" | 26297542 | |
hsa-miR-125a-3p | glioblastoma | Apoptosis pathway | "miR 29b and miR 125a regulate podoplanin and suppr ......" | 20665731 | |
hsa-miR-125a-3p | glioblastoma | cell cycle pathway | "An unbiased functional microRNA screen identified ......" | 27399532 | |
hsa-miR-125a-3p | liver cancer | mTOR signaling pathway | "miR 125a inhibits the migration and invasion of li ......" | 26622553 | Western blot; Colony formation; Transwell assay |
hsa-miR-125a-3p | lung cancer | Apoptosis pathway | "MicroRNA HSA miR 125a 5p induces apoptosis by acti ......" | 21777146 | |
hsa-miR-125a-3p | lung cancer | Apoptosis pathway | "MicroRNA hsa miR 125a 3p activates p53 and induces ......" | 24044511 | |
hsa-miR-125a-3p | ovarian cancer | Apoptosis pathway | "miRNA mimics and miRNA inhibitors were used in qua ......" | 26646586 | Western blot; Luciferase |
hsa-miR-125a-3p | pancreatic cancer | cell cycle pathway; Apoptosis pathway | "Effects of miR 125a 5p on Cell ProliferationApopto ......" | 27594154 | Flow cytometry |
hsa-miR-125a-3p | prostate cancer | Apoptosis pathway | "MicroRNA miR 125a 3p modulates molecular pathway o ......" | 25594017 |
Reported cancer prognosis affected by hsa-miR-125a-3p
miRNA | cancer | prognosis | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-125a-3p | acute myeloid leukemia | drug resistance; progression | "miR 125a regulates cell cycle proliferation and ap ......" | 24484870 | |
hsa-miR-125a-3p | bladder cancer | poor survival | "We identified an eight-miRNA signature including t ......" | 25991007 | |
hsa-miR-125a-3p | breast cancer | tumorigenesis | "Germline mutation of microRNA 125a is associated w ......" | 19411564 | |
hsa-miR-125a-3p | breast cancer | cell migration | "MicroRNA 125a represses cell growth by targeting H ......" | 19875930 | |
hsa-miR-125a-3p | breast cancer | tumor size | "Stem-loop real-time RT-PCR was used to detect the ......" | 25047098 | |
hsa-miR-125a-3p | breast cancer | tumorigenesis | "miR 125a 5p is a prognostic biomarker that targets ......" | 25504437 | |
hsa-miR-125a-3p | breast cancer | poor survival | "Association between miR 125a rs12976445 and surviv ......" | 25628797 | |
hsa-miR-125a-3p | breast cancer | malignant trasformation | "MicroRNA 125a influences breast cancer stem cells ......" | 25962054 | |
hsa-miR-125a-3p | breast cancer | malignant trasformation; metastasis; tumor size | "miR 125a 5p expression is associated with the age ......" | 26782438 | |
hsa-miR-125a-3p | breast cancer | drug resistance; staging | "Enforced expression of hsa miR 125a 3p in breast c ......" | 27693788 | |
hsa-miR-125a-3p | cervical and endocervical cancer | metastasis; staging; tumor size; tumorigenesis; progression | "MiR 125a suppresses tumor growth invasion and meta ......" | 26389681 | Luciferase |
hsa-miR-125a-3p | cervical and endocervical cancer | drug resistance | "MiR 125a promotes paclitaxel sensitivity in cervic ......" | 26878391 | |
hsa-miR-125a-3p | colorectal cancer | progression | "Clinicopathological significance of microRNA 21 an ......" | 19921579 | |
hsa-miR-125a-3p | esophageal cancer | staging; poor survival | "Five polymorphisms miR-146a rs2910164 miR-196a2 rs ......" | 24288122 | |
hsa-miR-125a-3p | gastric cancer | staging; metastasis; malignant trasformation; worse prognosis; tumor size; poor survival | "Down regulation of miR 125a 3p in human gastric ca ......" | 22322911 | |
hsa-miR-125a-3p | glioblastoma | drug resistance | "An unbiased functional microRNA screen identified ......" | 27399532 | |
hsa-miR-125a-3p | liver cancer | metastasis; tumorigenesis; malignant trasformation | "Ectopic expression of MiR 125a inhibits the prolif ......" | 22768249 | Western blot; Luciferase; RNAi |
hsa-miR-125a-3p | liver cancer | malignant trasformation | "miR 125a inhibits the migration and invasion of li ......" | 26622553 | Western blot; Colony formation; Transwell assay |
hsa-miR-125a-3p | lung cancer | metastasis | "A microarray was performed to analyze metastasis-r ......" | 22104216 | |
hsa-miR-125a-3p | lung squamous cell cancer | metastasis; staging; cell migration | "Hsa miR 125a 3p and hsa miR 125a 5p are downregula ......" | 20569443 | |
hsa-miR-125a-3p | lung squamous cell cancer | progression; worse prognosis | "Differential expression of miR 125a 5p and let 7e ......" | 24945821 | |
hsa-miR-125a-3p | ovarian cancer | cell migration | "miRNA mimics and miRNA inhibitors were used in qua ......" | 26646586 | Western blot; Luciferase |
hsa-miR-125a-3p | ovarian cancer | metastasis; staging | "MiR 125a regulates ovarian cancer proliferation an ......" | 27133078 | Western blot; Luciferase; MTT assay; Transwell assay |
hsa-miR-125a-3p | pancreatic cancer | drug resistance | "MiR 125a regulates chemo sensitivity to gemcitabin ......" | 26758190 | Luciferase |
hsa-miR-125a-3p | prostate cancer | motility | "MicroRNA miR 125a 3p modulates molecular pathway o ......" | 25594017 | |
hsa-miR-125a-3p | retinoblastoma | staging; progression | "Suppression of microRNA 125a 5p upregulates the TA ......" | 27094723 |
Reported gene related to hsa-miR-125a-3p
miRNA | cancer | gene | reporting | PUBMED |
---|---|---|---|---|
hsa-miR-125a-3p | acute myeloid leukemia | EGFR | "miR 125a regulates cell cycle proliferation and ap ......" | 24484870 |
hsa-miR-125a-3p | ovarian cancer | EGFR | "We report that EGFR signaling leads to transcripti ......" | 19881956 |
hsa-miR-125a-3p | retinoblastoma | EGFR | "Suppression of microRNA 125a 5p upregulates the TA ......" | 27094723 |
hsa-miR-125a-3p | lung cancer | EGF | "Epidermal growth factor receptor regulated miR 125 ......" | 19702827 |
hsa-miR-125a-3p | ovarian cancer | EGF | "The epidermal growth factor receptor responsive mi ......" | 19881956 |
hsa-miR-125a-3p | cervical and endocervical cancer | STAT3 | "MiR 125a suppresses tumor growth invasion and meta ......" | 26389681 |
hsa-miR-125a-3p | cervical and endocervical cancer | STAT3 | "MiR 125a promotes paclitaxel sensitivity in cervic ......" | 26878391 |
hsa-miR-125a-3p | breast cancer | TAZ | "Modulation of miR-125a led to a change in the acti ......" | 25962054 |
hsa-miR-125a-3p | retinoblastoma | TAZ | "Suppression of microRNA 125a 5p upregulates the TA ......" | 27094723 |
hsa-miR-125a-3p | cervical and endocervical cancer | TP53 | "Mechanistically inactivation of miR-125a during ce ......" | 26389681 |
hsa-miR-125a-3p | lung cancer | TP53 | "In addition wild-type p53 mRNA and protein express ......" | 24044511 |
hsa-miR-125a-3p | cervical and endocervical cancer | ABL2 | "MicroRNA 125a 5p modulates human cervical carcinom ......" | 26766902 |
hsa-miR-125a-3p | ovarian cancer | ARID3B | "We identify AT-rich interactive domain 3B ARID3B a ......" | 19881956 |
hsa-miR-125a-3p | breast cancer | BRCA1 | "From a mechanistic standpoint hsa-miR-125a-3p dire ......" | 27693788 |
hsa-miR-125a-3p | ovarian cancer | EIF4EBP1 | "Increased expression of miR-125a and miR-125b inhi ......" | 26646586 |
hsa-miR-125a-3p | breast cancer | ELAVL1 | "MicroRNA 125a represses cell growth by targeting H ......" | 19875930 |
hsa-miR-125a-3p | sarcoma | ERBB2 | "Moreover restoration of the expression of ErbB2 an ......" | 26966351 |
hsa-miR-125a-3p | ovarian cancer | ETV4 | "We report that EGFR signaling leads to transcripti ......" | 19881956 |
hsa-miR-125a-3p | prostate cancer | FYN | "We illustrate the role of miR-125a-3p in cellular ......" | 25594017 |
hsa-miR-125a-3p | ovarian cancer | GALNT14 | "MiR 125a regulates ovarian cancer proliferation an ......" | 27133078 |
hsa-miR-125a-3p | breast cancer | HDAC4 | "miR 125a 5p is a prognostic biomarker that targets ......" | 25504437 |
hsa-miR-125a-3p | breast cancer | HDAC5 | "HDAC inhibitors target HDAC5 upregulate microRNA 1 ......" | 25531695 |
hsa-miR-125a-3p | breast cancer | HDAC9 | "HDAC inhibitors target HDAC5 upregulate microRNA 1 ......" | 25531695 |
hsa-miR-125a-3p | colorectal cancer | IBSP | "We investigated the methylation status of miR-125 ......" | 26693202 |
hsa-miR-125a-3p | breast cancer | LIF | "MicroRNA 125a influences breast cancer stem cells ......" | 25962054 |
hsa-miR-125a-3p | breast cancer | LIFR | "Gain of function and loss of function of LIFR dire ......" | 25962054 |
hsa-miR-125a-3p | liver cancer | MMP11 | "Ectopic expression of MiR 125a inhibits the prolif ......" | 22768249 |
hsa-miR-125a-3p | prostate cancer | NAIF1 | "MicroRNA 125a 5p regulates cancer cell proliferati ......" | 26719710 |
hsa-miR-125a-3p | breast cancer | NR4A1 | "There were no significant correlations between miR ......" | 26782438 |
hsa-miR-125a-3p | glioblastoma | PDPN | "miR 29b and miR 125a regulate podoplanin and suppr ......" | 20665731 |
hsa-miR-125a-3p | lung squamous cell cancer | SCLC1 | "Cisplatin CDDP treatment of SCLC cells resulted in ......" | 25833836 |
hsa-miR-125a-3p | liver cancer | VEGFA | "Ectopic expression of MiR 125a inhibits the prolif ......" | 22768249 |
Expression profile in cancer corhorts:
Putative target regulations
miRNA | Gene | Cancer | Interaction | Correlation beta |
---|---|---|---|---|
hsa-miR-125a-3p | GLUL | 9 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; LIHC; LUSC; SARC | miRNAWalker2 validate | TCGA BLCA -0.116; TCGA BRCA -0.172; TCGA CESC -0.114; TCGA COAD -0.087; TCGA HNSC -0.202; TCGA KIRC -0.114; TCGA LIHC -0.33; TCGA LUSC -0.129; TCGA SARC -0.226 |
hsa-miR-125a-3p | TPK1 | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; KIRP; PRAD; SARC; THCA; STAD | MirTarget; miRanda | TCGA BLCA -0.115; TCGA BRCA -0.083; TCGA ESCA -0.286; TCGA HNSC -0.114; TCGA KIRC -0.203; TCGA KIRP -0.711; TCGA PRAD -0.103; TCGA SARC -0.152; TCGA THCA -0.07; TCGA STAD -0.168 |
hsa-miR-125a-3p | ASB16 | 9 cancers: BLCA; BRCA; CESC; LUAD; LUSC; SARC; THCA; STAD; UCEC | miRanda | TCGA BLCA -0.117; TCGA BRCA -0.152; TCGA CESC -0.146; TCGA LUAD -0.19; TCGA LUSC -0.199; TCGA SARC -0.388; TCGA THCA -0.104; TCGA STAD -0.121; TCGA UCEC -0.12 |
hsa-miR-125a-3p | CAPN3 | 10 cancers: BLCA; BRCA; ESCA; KIRC; KIRP; LIHC; LUAD; SARC; STAD; UCEC | miRanda | TCGA BLCA -0.136; TCGA BRCA -0.131; TCGA ESCA -0.136; TCGA KIRC -0.318; TCGA KIRP -0.233; TCGA LIHC -0.161; TCGA LUAD -0.24; TCGA SARC -0.323; TCGA STAD -0.153; TCGA UCEC -0.167 |
hsa-miR-125a-3p | TATDN3 | 10 cancers: BLCA; ESCA; HNSC; LIHC; LUAD; PRAD; SARC; THCA; STAD; UCEC | miRanda | TCGA BLCA -0.053; TCGA ESCA -0.084; TCGA HNSC -0.061; TCGA LIHC -0.086; TCGA LUAD -0.076; TCGA PRAD -0.051; TCGA SARC -0.073; TCGA THCA -0.085; TCGA STAD -0.061; TCGA UCEC -0.078 |
hsa-miR-125a-3p | AKAP1 | 11 cancers: BLCA; ESCA; KIRP; LGG; LIHC; LUSC; OV; PAAD; SARC; STAD; UCEC | miRanda | TCGA BLCA -0.066; TCGA ESCA -0.138; TCGA KIRP -0.118; TCGA LGG -0.079; TCGA LIHC -0.101; TCGA LUSC -0.111; TCGA OV -0.095; TCGA PAAD -0.188; TCGA SARC -0.595; TCGA STAD -0.061; TCGA UCEC -0.086 |
hsa-miR-125a-3p | HAUS4 | 12 cancers: BLCA; HNSC; KIRP; LGG; LIHC; LUSC; OV; PAAD; PRAD; SARC; THCA; UCEC | miRanda | TCGA BLCA -0.06; TCGA HNSC -0.057; TCGA KIRP -0.097; TCGA LGG -0.1; TCGA LIHC -0.175; TCGA LUSC -0.102; TCGA OV -0.182; TCGA PAAD -0.064; TCGA PRAD -0.065; TCGA SARC -0.096; TCGA THCA -0.067; TCGA UCEC -0.118 |
hsa-miR-125a-3p | CELF6 | 12 cancers: BLCA; CESC; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; SARC; THCA; UCEC | miRanda | TCGA BLCA -0.105; TCGA CESC -0.173; TCGA ESCA -0.201; TCGA HNSC -0.25; TCGA KIRP -0.265; TCGA LGG -0.138; TCGA LIHC -0.295; TCGA LUAD -0.318; TCGA LUSC -0.174; TCGA SARC -0.256; TCGA THCA -0.191; TCGA UCEC -0.149 |
hsa-miR-125a-3p | NDUFS7 | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PRAD; THCA | miRanda | TCGA BLCA -0.099; TCGA BRCA -0.102; TCGA CESC -0.092; TCGA HNSC -0.164; TCGA KIRP -0.108; TCGA LIHC -0.083; TCGA LUAD -0.094; TCGA LUSC -0.127; TCGA OV -0.169; TCGA PRAD -0.11; TCGA THCA -0.152 |
hsa-miR-125a-3p | BTG1 | 9 cancers: BLCA; CESC; HNSC; KIRC; LGG; LUSC; SARC; THCA; UCEC | miRanda | TCGA BLCA -0.078; TCGA CESC -0.072; TCGA HNSC -0.165; TCGA KIRC -0.155; TCGA LGG -0.104; TCGA LUSC -0.086; TCGA SARC -0.183; TCGA THCA -0.126; TCGA UCEC -0.205 |
hsa-miR-125a-3p | FMO3 | 10 cancers: BLCA; BRCA; CESC; HNSC; LGG; LIHC; PRAD; SARC; THCA; STAD | miRanda | TCGA BLCA -0.298; TCGA BRCA -0.118; TCGA CESC -0.482; TCGA HNSC -0.24; TCGA LGG -0.101; TCGA LIHC -0.471; TCGA PRAD -0.156; TCGA SARC -0.361; TCGA THCA -0.237; TCGA STAD -0.163 |
hsa-miR-125a-3p | ZNF546 | 9 cancers: BLCA; BRCA; ESCA; KIRC; LIHC; LUAD; LUSC; SARC; STAD | miRanda | TCGA BLCA -0.081; TCGA BRCA -0.054; TCGA ESCA -0.136; TCGA KIRC -0.084; TCGA LIHC -0.084; TCGA LUAD -0.065; TCGA LUSC -0.082; TCGA SARC -0.08; TCGA STAD -0.133 |
hsa-miR-125a-3p | CCDC159 | 12 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRP; LIHC; LUAD; PRAD; SARC; THCA; UCEC | miRanda | TCGA BLCA -0.094; TCGA BRCA -0.178; TCGA CESC -0.076; TCGA ESCA -0.102; TCGA HNSC -0.123; TCGA KIRP -0.082; TCGA LIHC -0.138; TCGA LUAD -0.168; TCGA PRAD -0.151; TCGA SARC -0.133; TCGA THCA -0.1; TCGA UCEC -0.142 |
hsa-miR-125a-3p | OMA1 | 14 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; OV; PRAD; SARC; STAD; UCEC | miRanda | TCGA BLCA -0.057; TCGA BRCA -0.077; TCGA CESC -0.096; TCGA ESCA -0.081; TCGA HNSC -0.121; TCGA KIRP -0.095; TCGA LIHC -0.095; TCGA LUAD -0.101; TCGA LUSC -0.074; TCGA OV -0.16; TCGA PRAD -0.103; TCGA SARC -0.172; TCGA STAD -0.085; TCGA UCEC -0.118 |
hsa-miR-125a-3p | CIRBP | 9 cancers: BLCA; BRCA; CESC; HNSC; LGG; LIHC; PRAD; STAD; UCEC | miRanda | TCGA BLCA -0.135; TCGA BRCA -0.122; TCGA CESC -0.087; TCGA HNSC -0.095; TCGA LGG -0.106; TCGA LIHC -0.083; TCGA PRAD -0.057; TCGA STAD -0.103; TCGA UCEC -0.134 |
hsa-miR-125a-3p | P2RX7 | 9 cancers: BLCA; CESC; COAD; KIRC; KIRP; LGG; SARC; THCA; UCEC | miRanda | TCGA BLCA -0.159; TCGA CESC -0.361; TCGA COAD -0.21; TCGA KIRC -0.427; TCGA KIRP -0.239; TCGA LGG -0.187; TCGA SARC -0.374; TCGA THCA -0.277; TCGA UCEC -0.324 |
hsa-miR-125a-3p | ZNF277 | 9 cancers: BLCA; KIRC; KIRP; LGG; LIHC; LUSC; PRAD; STAD; UCEC | miRanda | TCGA BLCA -0.07; TCGA KIRC -0.069; TCGA KIRP -0.091; TCGA LGG -0.089; TCGA LIHC -0.069; TCGA LUSC -0.06; TCGA PRAD -0.089; TCGA STAD -0.104; TCGA UCEC -0.098 |
hsa-miR-125a-3p | NT5DC1 | 11 cancers: BLCA; BRCA; ESCA; HNSC; LIHC; LUSC; OV; SARC; THCA; STAD; UCEC | miRanda | TCGA BLCA -0.085; TCGA BRCA -0.076; TCGA ESCA -0.119; TCGA HNSC -0.056; TCGA LIHC -0.116; TCGA LUSC -0.075; TCGA OV -0.185; TCGA SARC -0.177; TCGA THCA -0.089; TCGA STAD -0.11; TCGA UCEC -0.057 |
hsa-miR-125a-3p | ZNF782 | 9 cancers: BLCA; CESC; COAD; ESCA; LIHC; LUSC; PAAD; STAD; UCEC | miRanda | TCGA BLCA -0.074; TCGA CESC -0.062; TCGA COAD -0.076; TCGA ESCA -0.128; TCGA LIHC -0.056; TCGA LUSC -0.12; TCGA PAAD -0.102; TCGA STAD -0.145; TCGA UCEC -0.081 |
hsa-miR-125a-3p | CCDC146 | 9 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; KIRP; SARC; STAD | miRanda | TCGA BLCA -0.113; TCGA BRCA -0.114; TCGA CESC -0.231; TCGA ESCA -0.2; TCGA HNSC -0.211; TCGA KIRC -0.326; TCGA KIRP -0.322; TCGA SARC -0.421; TCGA STAD -0.243 |
hsa-miR-125a-3p | ZNF280D | 9 cancers: BLCA; BRCA; ESCA; KIRC; LIHC; OV; PAAD; STAD; UCEC | miRanda | TCGA BLCA -0.093; TCGA BRCA -0.064; TCGA ESCA -0.082; TCGA KIRC -0.073; TCGA LIHC -0.081; TCGA OV -0.107; TCGA PAAD -0.067; TCGA STAD -0.122; TCGA UCEC -0.18 |
hsa-miR-125a-3p | FBXO4 | 10 cancers: BLCA; BRCA; HNSC; KIRC; LIHC; LUAD; OV; PRAD; SARC; STAD | miRanda | TCGA BLCA -0.074; TCGA BRCA -0.067; TCGA HNSC -0.081; TCGA KIRC -0.1; TCGA LIHC -0.127; TCGA LUAD -0.083; TCGA OV -0.188; TCGA PRAD -0.073; TCGA SARC -0.12; TCGA STAD -0.081 |
hsa-miR-125a-3p | RPS15A | 9 cancers: BLCA; HNSC; KIRC; KIRP; LGG; OV; PAAD; PRAD; STAD | miRanda | TCGA BLCA -0.087; TCGA HNSC -0.082; TCGA KIRC -0.116; TCGA KIRP -0.107; TCGA LGG -0.127; TCGA OV -0.224; TCGA PAAD -0.108; TCGA PRAD -0.115; TCGA STAD -0.104 |
hsa-miR-125a-3p | NT5M | 10 cancers: BLCA; HNSC; KIRP; LGG; LIHC; LUAD; OV; PRAD; SARC; THCA | miRanda | TCGA BLCA -0.303; TCGA HNSC -0.319; TCGA KIRP -0.269; TCGA LGG -0.106; TCGA LIHC -0.187; TCGA LUAD -0.116; TCGA OV -0.209; TCGA PRAD -0.197; TCGA SARC -0.441; TCGA THCA -0.132 |
hsa-miR-125a-3p | CRYL1 | 11 cancers: BLCA; CESC; ESCA; HNSC; LGG; LIHC; OV; PAAD; PRAD; THCA; UCEC | miRanda | TCGA BLCA -0.075; TCGA CESC -0.096; TCGA ESCA -0.255; TCGA HNSC -0.127; TCGA LGG -0.081; TCGA LIHC -0.311; TCGA OV -0.325; TCGA PAAD -0.157; TCGA PRAD -0.1; TCGA THCA -0.053; TCGA UCEC -0.348 |
hsa-miR-125a-3p | LY9 | 10 cancers: BLCA; CESC; ESCA; HNSC; KIRC; LUAD; LUSC; SARC; THCA; UCEC | miRanda | TCGA BLCA -0.212; TCGA CESC -0.285; TCGA ESCA -0.228; TCGA HNSC -0.317; TCGA KIRC -0.399; TCGA LUAD -0.15; TCGA LUSC -0.201; TCGA SARC -0.267; TCGA THCA -0.372; TCGA UCEC -0.251 |
hsa-miR-125a-3p | ATP6V0A1 | 9 cancers: BLCA; CESC; ESCA; HNSC; KIRP; LGG; LIHC; SARC; UCEC | miRanda | TCGA BLCA -0.058; TCGA CESC -0.086; TCGA ESCA -0.1; TCGA HNSC -0.057; TCGA KIRP -0.2; TCGA LGG -0.061; TCGA LIHC -0.07; TCGA SARC -0.094; TCGA UCEC -0.087 |
hsa-miR-125a-3p | MYO15B | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; THCA; UCEC | miRanda | TCGA BLCA -0.151; TCGA BRCA -0.125; TCGA ESCA -0.309; TCGA HNSC -0.381; TCGA KIRC -0.365; TCGA KIRP -0.541; TCGA LIHC -0.103; TCGA LUAD -0.351; TCGA THCA -0.113; TCGA UCEC -0.203 |
hsa-miR-125a-3p | MPPE1 | 9 cancers: BLCA; HNSC; KIRP; LIHC; LUSC; OV; SARC; STAD; UCEC | miRanda | TCGA BLCA -0.096; TCGA HNSC -0.062; TCGA KIRP -0.085; TCGA LIHC -0.07; TCGA LUSC -0.064; TCGA OV -0.125; TCGA SARC -0.144; TCGA STAD -0.074; TCGA UCEC -0.096 |
hsa-miR-125a-3p | MPND | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; THCA | miRanda | TCGA BLCA -0.082; TCGA BRCA -0.114; TCGA CESC -0.103; TCGA HNSC -0.162; TCGA KIRP -0.092; TCGA LIHC -0.194; TCGA LUAD -0.094; TCGA LUSC -0.056; TCGA PAAD -0.09; TCGA PRAD -0.13; TCGA THCA -0.146 |
hsa-miR-125a-3p | CLK4 | 11 cancers: BLCA; CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; PRAD; STAD; UCEC | miRanda | TCGA BLCA -0.075; TCGA CESC -0.096; TCGA HNSC -0.113; TCGA KIRC -0.211; TCGA KIRP -0.174; TCGA LGG -0.099; TCGA LIHC -0.089; TCGA LUAD -0.115; TCGA PRAD -0.056; TCGA STAD -0.101; TCGA UCEC -0.061 |
hsa-miR-125a-3p | SAR1B | 11 cancers: BRCA; ESCA; KIRC; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD | MirTarget | TCGA BRCA -0.067; TCGA ESCA -0.077; TCGA KIRC -0.131; TCGA LIHC -0.187; TCGA LUAD -0.107; TCGA LUSC -0.092; TCGA OV -0.124; TCGA PRAD -0.087; TCGA SARC -0.13; TCGA THCA -0.07; TCGA STAD -0.105 |
hsa-miR-125a-3p | GATM | 9 cancers: BRCA; CESC; ESCA; HNSC; KIRP; LIHC; OV; THCA; UCEC | PITA; miRanda | TCGA BRCA -0.242; TCGA CESC -0.267; TCGA ESCA -0.273; TCGA HNSC -0.356; TCGA KIRP -0.316; TCGA LIHC -0.243; TCGA OV -0.236; TCGA THCA -0.146; TCGA UCEC -0.24 |
hsa-miR-125a-3p | EXOC6 | 10 cancers: BRCA; COAD; ESCA; HNSC; LGG; LUSC; PRAD; SARC; STAD; UCEC | miRanda | TCGA BRCA -0.091; TCGA COAD -0.079; TCGA ESCA -0.151; TCGA HNSC -0.15; TCGA LGG -0.062; TCGA LUSC -0.091; TCGA PRAD -0.119; TCGA SARC -0.2; TCGA STAD -0.094; TCGA UCEC -0.14 |
hsa-miR-125a-3p | RFFL | 10 cancers: BRCA; CESC; COAD; HNSC; KIRC; LIHC; LUSC; PRAD; SARC; UCEC | miRanda | TCGA BRCA -0.075; TCGA CESC -0.111; TCGA COAD -0.067; TCGA HNSC -0.104; TCGA KIRC -0.16; TCGA LIHC -0.092; TCGA LUSC -0.134; TCGA PRAD -0.076; TCGA SARC -0.191; TCGA UCEC -0.078 |
hsa-miR-125a-3p | ALPK1 | 9 cancers: BRCA; CESC; ESCA; KIRC; KIRP; LUAD; PAAD; SARC; STAD | miRanda | TCGA BRCA -0.081; TCGA CESC -0.091; TCGA ESCA -0.093; TCGA KIRC -0.207; TCGA KIRP -0.073; TCGA LUAD -0.096; TCGA PAAD -0.134; TCGA SARC -0.212; TCGA STAD -0.123 |
hsa-miR-125a-3p | ZNF700 | 11 cancers: BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; SARC; THCA; STAD | miRanda | TCGA BRCA -0.063; TCGA CESC -0.06; TCGA ESCA -0.108; TCGA HNSC -0.098; TCGA KIRC -0.158; TCGA KIRP -0.107; TCGA LUAD -0.113; TCGA LUSC -0.122; TCGA SARC -0.254; TCGA THCA -0.054; TCGA STAD -0.094 |
hsa-miR-125a-3p | ECHDC2 | 9 cancers: BRCA; CESC; HNSC; KIRP; LIHC; LUAD; PRAD; SARC; UCEC | miRanda | TCGA BRCA -0.131; TCGA CESC -0.1; TCGA HNSC -0.265; TCGA KIRP -0.091; TCGA LIHC -0.203; TCGA LUAD -0.147; TCGA PRAD -0.1; TCGA SARC -0.321; TCGA UCEC -0.124 |
hsa-miR-125a-3p | CC2D1A | 9 cancers: BRCA; CESC; ESCA; HNSC; KIRP; LIHC; LUAD; LUSC; SARC | miRanda | TCGA BRCA -0.059; TCGA CESC -0.117; TCGA ESCA -0.065; TCGA HNSC -0.083; TCGA KIRP -0.07; TCGA LIHC -0.051; TCGA LUAD -0.105; TCGA LUSC -0.161; TCGA SARC -0.088 |
hsa-miR-125a-3p | MPP7 | 9 cancers: BRCA; CESC; COAD; HNSC; LUSC; SARC; THCA; STAD; UCEC | miRanda | TCGA BRCA -0.183; TCGA CESC -0.337; TCGA COAD -0.243; TCGA HNSC -0.155; TCGA LUSC -0.153; TCGA SARC -1.101; TCGA THCA -0.148; TCGA STAD -0.29; TCGA UCEC -0.179 |
hsa-miR-125a-3p | TOM1L1 | 10 cancers: BRCA; ESCA; HNSC; LIHC; LUAD; OV; PAAD; SARC; STAD; UCEC | miRanda | TCGA BRCA -0.085; TCGA ESCA -0.092; TCGA HNSC -0.077; TCGA LIHC -0.18; TCGA LUAD -0.133; TCGA OV -0.166; TCGA PAAD -0.162; TCGA SARC -0.429; TCGA STAD -0.096; TCGA UCEC -0.097 |
hsa-miR-125a-3p | FAM151B | 10 cancers: BRCA; CESC; HNSC; KIRC; LUAD; OV; PRAD; THCA; STAD; UCEC | miRanda | TCGA BRCA -0.091; TCGA CESC -0.162; TCGA HNSC -0.101; TCGA KIRC -0.107; TCGA LUAD -0.071; TCGA OV -0.185; TCGA PRAD -0.131; TCGA THCA -0.092; TCGA STAD -0.132; TCGA UCEC -0.103 |
hsa-miR-125a-3p | AQP11 | 9 cancers: BRCA; KIRC; KIRP; LGG; LIHC; LUAD; OV; PRAD; THCA | miRanda | TCGA BRCA -0.123; TCGA KIRC -0.145; TCGA KIRP -0.124; TCGA LGG -0.105; TCGA LIHC -0.261; TCGA LUAD -0.133; TCGA OV -0.191; TCGA PRAD -0.325; TCGA THCA -0.074 |
hsa-miR-125a-3p | MYL5 | 9 cancers: BRCA; CESC; HNSC; KIRC; KIRP; LIHC; LUAD; PRAD; THCA | miRanda | TCGA BRCA -0.074; TCGA CESC -0.088; TCGA HNSC -0.248; TCGA KIRC -0.146; TCGA KIRP -0.194; TCGA LIHC -0.113; TCGA LUAD -0.173; TCGA PRAD -0.231; TCGA THCA -0.082 |
hsa-miR-125a-3p | CSAD | 11 cancers: BRCA; CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; THCA; STAD | miRanda | TCGA BRCA -0.128; TCGA CESC -0.121; TCGA HNSC -0.259; TCGA KIRC -0.233; TCGA KIRP -0.15; TCGA LGG -0.09; TCGA LIHC -0.122; TCGA LUAD -0.308; TCGA LUSC -0.101; TCGA THCA -0.184; TCGA STAD -0.133 |
hsa-miR-125a-3p | FMO5 | 10 cancers: BRCA; COAD; ESCA; HNSC; LIHC; LUAD; PAAD; PRAD; SARC; UCEC | miRanda | TCGA BRCA -0.445; TCGA COAD -0.222; TCGA ESCA -0.375; TCGA HNSC -0.136; TCGA LIHC -0.392; TCGA LUAD -0.241; TCGA PAAD -0.439; TCGA PRAD -0.34; TCGA SARC -0.426; TCGA UCEC -0.529 |
hsa-miR-125a-3p | RWDD2A | 11 cancers: BRCA; ESCA; KIRC; KIRP; LGG; LIHC; LUAD; OV; PAAD; SARC; THCA | miRanda | TCGA BRCA -0.053; TCGA ESCA -0.118; TCGA KIRC -0.124; TCGA KIRP -0.096; TCGA LGG -0.099; TCGA LIHC -0.057; TCGA LUAD -0.057; TCGA OV -0.168; TCGA PAAD -0.114; TCGA SARC -0.065; TCGA THCA -0.053 |
hsa-miR-125a-3p | EPB41L4A | 9 cancers: BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LGG; SARC; STAD | miRanda | TCGA BRCA -0.207; TCGA CESC -0.089; TCGA ESCA -0.16; TCGA HNSC -0.154; TCGA KIRC -0.133; TCGA KIRP -0.131; TCGA LGG -0.068; TCGA SARC -0.105; TCGA STAD -0.13 |
hsa-miR-125a-3p | KLHDC2 | 10 cancers: BRCA; COAD; HNSC; KIRP; LGG; LIHC; OV; SARC; STAD; UCEC | miRanda | TCGA BRCA -0.066; TCGA COAD -0.103; TCGA HNSC -0.058; TCGA KIRP -0.105; TCGA LGG -0.066; TCGA LIHC -0.139; TCGA OV -0.201; TCGA SARC -0.143; TCGA STAD -0.093; TCGA UCEC -0.072 |
hsa-miR-125a-3p | ATG16L2 | 12 cancers: BRCA; CESC; ESCA; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; SARC; THCA; STAD | miRanda | TCGA BRCA -0.091; TCGA CESC -0.15; TCGA ESCA -0.111; TCGA HNSC -0.273; TCGA KIRC -0.249; TCGA KIRP -0.314; TCGA LGG -0.068; TCGA LUAD -0.28; TCGA LUSC -0.104; TCGA SARC -0.224; TCGA THCA -0.09; TCGA STAD -0.066 |
hsa-miR-125a-3p | ACADSB | 9 cancers: BRCA; CESC; HNSC; LGG; LIHC; PRAD; THCA; STAD; UCEC | miRanda | TCGA BRCA -0.175; TCGA CESC -0.117; TCGA HNSC -0.15; TCGA LGG -0.071; TCGA LIHC -0.192; TCGA PRAD -0.078; TCGA THCA -0.12; TCGA STAD -0.13; TCGA UCEC -0.142 |
hsa-miR-125a-3p | PEX7 | 9 cancers: BRCA; COAD; ESCA; HNSC; LGG; LIHC; OV; PRAD; UCEC | miRanda | TCGA BRCA -0.087; TCGA COAD -0.072; TCGA ESCA -0.121; TCGA HNSC -0.063; TCGA LGG -0.064; TCGA LIHC -0.069; TCGA OV -0.157; TCGA PRAD -0.101; TCGA UCEC -0.123 |
hsa-miR-125a-3p | WDR90 | 9 cancers: BRCA; HNSC; KIRC; KIRP; LUAD; LUSC; PRAD; SARC; THCA | miRanda | TCGA BRCA -0.08; TCGA HNSC -0.102; TCGA KIRC -0.225; TCGA KIRP -0.265; TCGA LUAD -0.211; TCGA LUSC -0.091; TCGA PRAD -0.099; TCGA SARC -0.111; TCGA THCA -0.061 |
hsa-miR-125a-3p | LYST | 9 cancers: BRCA; CESC; ESCA; KIRC; LIHC; LUAD; SARC; STAD; UCEC | miRanda | TCGA BRCA -0.103; TCGA CESC -0.123; TCGA ESCA -0.118; TCGA KIRC -0.134; TCGA LIHC -0.091; TCGA LUAD -0.078; TCGA SARC -0.189; TCGA STAD -0.113; TCGA UCEC -0.289 |
hsa-miR-125a-3p | ATP8B1 | 9 cancers: BRCA; CESC; COAD; ESCA; HNSC; LUSC; SARC; STAD; UCEC | miRanda | TCGA BRCA -0.165; TCGA CESC -0.13; TCGA COAD -0.083; TCGA ESCA -0.187; TCGA HNSC -0.181; TCGA LUSC -0.11; TCGA SARC -0.345; TCGA STAD -0.11; TCGA UCEC -0.196 |
hsa-miR-125a-3p | SH3RF2 | 9 cancers: BRCA; CESC; KIRC; KIRP; LIHC; PRAD; SARC; THCA; STAD | miRanda | TCGA BRCA -0.285; TCGA CESC -0.29; TCGA KIRC -0.246; TCGA KIRP -0.297; TCGA LIHC -0.329; TCGA PRAD -0.145; TCGA SARC -0.589; TCGA THCA -0.221; TCGA STAD -0.205 |
hsa-miR-125a-3p | FGGY | 9 cancers: BRCA; KIRC; KIRP; LIHC; OV; PRAD; SARC; THCA; UCEC | miRanda | TCGA BRCA -0.078; TCGA KIRC -0.126; TCGA KIRP -0.159; TCGA LIHC -0.335; TCGA OV -0.253; TCGA PRAD -0.088; TCGA SARC -0.183; TCGA THCA -0.052; TCGA UCEC -0.187 |
hsa-miR-125a-3p | HEMK1 | 10 cancers: BRCA; ESCA; HNSC; KIRP; LIHC; LUAD; OV; PRAD; SARC; THCA | miRNATAP | TCGA BRCA -0.057; TCGA ESCA -0.08; TCGA HNSC -0.085; TCGA KIRP -0.196; TCGA LIHC -0.123; TCGA LUAD -0.12; TCGA OV -0.104; TCGA PRAD -0.099; TCGA SARC -0.142; TCGA THCA -0.12 |
hsa-miR-125a-3p | AHSA2 | 10 cancers: CESC; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; THCA; STAD | MirTarget | TCGA CESC -0.095; TCGA ESCA -0.11; TCGA HNSC -0.325; TCGA KIRC -0.325; TCGA KIRP -0.358; TCGA LIHC -0.119; TCGA LUAD -0.319; TCGA LUSC -0.168; TCGA THCA -0.22; TCGA STAD -0.121 |
hsa-miR-125a-3p | MRRF | 9 cancers: CESC; ESCA; KIRC; KIRP; LGG; LUSC; OV; PRAD; THCA | miRanda; miRNATAP | TCGA CESC -0.057; TCGA ESCA -0.079; TCGA KIRC -0.105; TCGA KIRP -0.146; TCGA LGG -0.064; TCGA LUSC -0.179; TCGA OV -0.163; TCGA PRAD -0.094; TCGA THCA -0.056 |
hsa-miR-125a-3p | ERI2 | 13 cancers: CESC; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; STAD | miRanda | TCGA CESC -0.091; TCGA ESCA -0.068; TCGA HNSC -0.068; TCGA KIRC -0.089; TCGA KIRP -0.134; TCGA LGG -0.074; TCGA LIHC -0.073; TCGA LUAD -0.07; TCGA LUSC -0.099; TCGA PAAD -0.082; TCGA PRAD -0.055; TCGA SARC -0.111; TCGA STAD -0.099 |
hsa-miR-125a-3p | COX18 | 9 cancers: CESC; KIRP; LIHC; LUAD; OV; PRAD; THCA; STAD; UCEC | miRanda | TCGA CESC -0.07; TCGA KIRP -0.109; TCGA LIHC -0.052; TCGA LUAD -0.093; TCGA OV -0.215; TCGA PRAD -0.072; TCGA THCA -0.127; TCGA STAD -0.14; TCGA UCEC -0.062 |
hsa-miR-125a-3p | CCDC7 | 11 cancers: CESC; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; PRAD; THCA; STAD; UCEC | miRanda | TCGA CESC -0.09; TCGA ESCA -0.088; TCGA HNSC -0.071; TCGA KIRC -0.167; TCGA LIHC -0.096; TCGA LUAD -0.059; TCGA LUSC -0.061; TCGA PRAD -0.094; TCGA THCA -0.095; TCGA STAD -0.118; TCGA UCEC -0.12 |
hsa-miR-125a-3p | ZCCHC6 | 9 cancers: CESC; COAD; ESCA; KIRC; LIHC; LUSC; PRAD; STAD; UCEC | miRanda | TCGA CESC -0.122; TCGA COAD -0.072; TCGA ESCA -0.124; TCGA KIRC -0.059; TCGA LIHC -0.148; TCGA LUSC -0.102; TCGA PRAD -0.115; TCGA STAD -0.109; TCGA UCEC -0.126 |
hsa-miR-125a-3p | NBR2 | 10 cancers: CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; SARC; THCA | miRanda | TCGA CESC -0.074; TCGA HNSC -0.16; TCGA KIRC -0.191; TCGA KIRP -0.278; TCGA LGG -0.087; TCGA LIHC -0.13; TCGA LUAD -0.109; TCGA LUSC -0.246; TCGA SARC -0.139; TCGA THCA -0.101 |
hsa-miR-125a-3p | MLX | 11 cancers: CESC; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PAAD; PRAD | miRanda | TCGA CESC -0.05; TCGA ESCA -0.066; TCGA HNSC -0.057; TCGA KIRC -0.07; TCGA KIRP -0.094; TCGA LIHC -0.115; TCGA LUAD -0.064; TCGA LUSC -0.074; TCGA OV -0.137; TCGA PAAD -0.068; TCGA PRAD -0.107 |
hsa-miR-125a-3p | WSB1 | 9 cancers: CESC; HNSC; KIRC; KIRP; LGG; LUAD; SARC; THCA; STAD | miRanda | TCGA CESC -0.053; TCGA HNSC -0.108; TCGA KIRC -0.204; TCGA KIRP -0.142; TCGA LGG -0.173; TCGA LUAD -0.182; TCGA SARC -0.083; TCGA THCA -0.116; TCGA STAD -0.076 |
hsa-miR-125a-3p | DHTKD1 | 9 cancers: CESC; ESCA; KIRC; LGG; LIHC; LUAD; LUSC; PRAD; THCA | miRanda | TCGA CESC -0.064; TCGA ESCA -0.084; TCGA KIRC -0.148; TCGA LGG -0.121; TCGA LIHC -0.248; TCGA LUAD -0.066; TCGA LUSC -0.07; TCGA PRAD -0.112; TCGA THCA -0.073 |
hsa-miR-125a-3p | NADSYN1 | 10 cancers: CESC; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; OV; PRAD; THCA | miRanda | TCGA CESC -0.109; TCGA HNSC -0.13; TCGA KIRC -0.125; TCGA KIRP -0.128; TCGA LIHC -0.077; TCGA LUAD -0.161; TCGA LUSC -0.222; TCGA OV -0.191; TCGA PRAD -0.076; TCGA THCA -0.122 |
hsa-miR-125a-3p | TMEM38B | 9 cancers: CESC; COAD; ESCA; LGG; LIHC; LUSC; OV; SARC; UCEC | miRanda | TCGA CESC -0.112; TCGA COAD -0.175; TCGA ESCA -0.111; TCGA LGG -0.062; TCGA LIHC -0.122; TCGA LUSC -0.189; TCGA OV -0.253; TCGA SARC -0.115; TCGA UCEC -0.152 |
hsa-miR-125a-3p | TYSND1 | 9 cancers: CESC; HNSC; KIRP; LGG; LUAD; LUSC; OV; PRAD; THCA | miRanda | TCGA CESC -0.078; TCGA HNSC -0.087; TCGA KIRP -0.066; TCGA LGG -0.161; TCGA LUAD -0.084; TCGA LUSC -0.153; TCGA OV -0.186; TCGA PRAD -0.103; TCGA THCA -0.09 |
hsa-miR-125a-3p | RNPC3 | 10 cancers: CESC; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; SARC; THCA; STAD | miRanda | TCGA CESC -0.071; TCGA COAD -0.067; TCGA ESCA -0.111; TCGA HNSC -0.086; TCGA KIRC -0.166; TCGA LUAD -0.171; TCGA LUSC -0.067; TCGA SARC -0.204; TCGA THCA -0.133; TCGA STAD -0.14 |
hsa-miR-125a-3p | NUDT13 | 11 cancers: CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; PRAD; THCA; STAD; UCEC | miRanda | TCGA CESC -0.096; TCGA HNSC -0.124; TCGA KIRC -0.22; TCGA KIRP -0.213; TCGA LGG -0.134; TCGA LIHC -0.179; TCGA LUAD -0.136; TCGA PRAD -0.121; TCGA THCA -0.074; TCGA STAD -0.189; TCGA UCEC -0.235 |
hsa-miR-125a-3p | UBN2 | 9 cancers: CESC; ESCA; HNSC; KIRC; KIRP; LGG; LUSC; STAD; UCEC | miRanda | TCGA CESC -0.103; TCGA ESCA -0.092; TCGA HNSC -0.058; TCGA KIRC -0.098; TCGA KIRP -0.109; TCGA LGG -0.072; TCGA LUSC -0.063; TCGA STAD -0.117; TCGA UCEC -0.06 |
hsa-miR-125a-3p | SAMD13 | 9 cancers: COAD; ESCA; HNSC; KIRP; OV; PAAD; PRAD; SARC; STAD | miRanda | TCGA COAD -0.142; TCGA ESCA -0.242; TCGA HNSC -0.234; TCGA KIRP -0.284; TCGA OV -0.252; TCGA PAAD -0.178; TCGA PRAD -0.171; TCGA SARC -0.303; TCGA STAD -0.157 |
hsa-miR-125a-3p | NUPL2 | 12 cancers: COAD; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PRAD; THCA; STAD | miRanda | TCGA COAD -0.078; TCGA HNSC -0.12; TCGA KIRC -0.083; TCGA KIRP -0.119; TCGA LGG -0.089; TCGA LIHC -0.05; TCGA LUAD -0.065; TCGA LUSC -0.117; TCGA OV -0.108; TCGA PRAD -0.063; TCGA THCA -0.055; TCGA STAD -0.073 |
hsa-miR-125a-3p | MRS2 | 9 cancers: COAD; HNSC; KIRC; KIRP; LGG; LUAD; LUSC; OV; PAAD | miRanda | TCGA COAD -0.058; TCGA HNSC -0.051; TCGA KIRC -0.096; TCGA KIRP -0.11; TCGA LGG -0.061; TCGA LUAD -0.052; TCGA LUSC -0.07; TCGA OV -0.196; TCGA PAAD -0.096 |
hsa-miR-125a-3p | SLC25A35 | 9 cancers: ESCA; HNSC; KIRP; LUAD; OV; PRAD; SARC; THCA; UCEC | PITA; miRNATAP | TCGA ESCA -0.108; TCGA HNSC -0.153; TCGA KIRP -0.136; TCGA LUAD -0.078; TCGA OV -0.141; TCGA PRAD -0.132; TCGA SARC -0.118; TCGA THCA -0.141; TCGA UCEC -0.313 |
hsa-miR-125a-3p | ACCS | 10 cancers: ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; OV; PRAD; SARC; THCA | miRanda | TCGA ESCA -0.149; TCGA HNSC -0.147; TCGA KIRC -0.215; TCGA KIRP -0.262; TCGA LIHC -0.146; TCGA LUAD -0.247; TCGA OV -0.235; TCGA PRAD -0.187; TCGA SARC -0.146; TCGA THCA -0.173 |
hsa-miR-125a-3p | ADAT2 | 9 cancers: ESCA; HNSC; KIRP; LGG; LUAD; LUSC; OV; THCA; STAD | miRanda | TCGA ESCA -0.111; TCGA HNSC -0.136; TCGA KIRP -0.224; TCGA LGG -0.088; TCGA LUAD -0.178; TCGA LUSC -0.131; TCGA OV -0.132; TCGA THCA -0.121; TCGA STAD -0.118 |
hsa-miR-125a-3p | GOLGA8A | 9 cancers: ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; THCA | miRanda | TCGA ESCA -0.156; TCGA HNSC -0.373; TCGA KIRC -0.291; TCGA KIRP -0.228; TCGA LGG -0.184; TCGA LIHC -0.153; TCGA LUAD -0.301; TCGA LUSC -0.229; TCGA THCA -0.162 |
hsa-miR-125a-3p | MRPS25 | 10 cancers: ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; PRAD; SARC; THCA | miRanda | TCGA ESCA -0.084; TCGA HNSC -0.135; TCGA KIRP -0.143; TCGA LGG -0.086; TCGA LIHC -0.075; TCGA LUAD -0.121; TCGA LUSC -0.113; TCGA PRAD -0.093; TCGA SARC -0.073; TCGA THCA -0.138 |
hsa-miR-125a-3p | HCG27 | 9 cancers: HNSC; KIRC; KIRP; LGG; LIHC; LUAD; PRAD; SARC; THCA | miRanda | TCGA HNSC -0.15; TCGA KIRC -0.429; TCGA KIRP -0.375; TCGA LGG -0.092; TCGA LIHC -0.098; TCGA LUAD -0.224; TCGA PRAD -0.219; TCGA SARC -0.402; TCGA THCA -0.246 |
hsa-miR-125a-3p | OSGEPL1 | 9 cancers: HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; STAD | miRanda | TCGA HNSC -0.072; TCGA KIRC -0.104; TCGA KIRP -0.122; TCGA LGG -0.116; TCGA LIHC -0.08; TCGA LUAD -0.063; TCGA LUSC -0.066; TCGA OV -0.107; TCGA STAD -0.066 |
hsa-miR-125a-3p | TAZ | 9 cancers: HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; THCA | miRanda | TCGA HNSC -0.132; TCGA KIRC -0.098; TCGA KIRP -0.175; TCGA LGG -0.056; TCGA LIHC -0.093; TCGA LUAD -0.087; TCGA LUSC -0.098; TCGA OV -0.198; TCGA THCA -0.096 |
hsa-miR-125a-3p | FOXRED1 | 9 cancers: KIRP; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA | miRanda | TCGA KIRP -0.08; TCGA LGG -0.074; TCGA LIHC -0.103; TCGA LUAD -0.059; TCGA LUSC -0.074; TCGA OV -0.107; TCGA PRAD -0.071; TCGA SARC -0.06; TCGA THCA -0.102 |
Enriched cancer pathways of putative targets